Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Unknown 4 Recruiting 2 Withdrawn 1 Terminated 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 437 Neoplasms 322 Carcinoma, Non-Small-Cell Lung 250 Prostatic Neoplasms 240 Lung Neoplasms 174 Colorectal Neoplasms 156 Pancreatic Neoplasms 148 Neoplasm Metastasis 142 Leukemia, Myeloid, Acute 140 Multiple Myeloma 130 Lymphoma 127 Carcinoma, Hepatocellular 127 Ovarian Neoplasms 109 Melanoma 109 Brain Neoplasms 101 Recurrence 100 Head and Neck Neoplasms 100 Leukemia, Lymphocytic, Chronic, B-Cell 96 Leukemia 96 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Glioblastoma 85 Lymphoma, Non-Hodgkin 83 Colonic Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 76 Lymphoma, Follicular 76 Carcinoma, Renal Cell 74 Lymphoma, Large B-Cell, Diffuse 71 Hematologic Neoplasms 69 Sarcoma 60 Stomach Neoplasms 58

Interventions

Certolizumab Pegol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Fistula × Clear all

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

Data powered by HemOnc (CC BY 4.0) Colophon ⚡